(Q58055167)

1

0 references

author name string

Miguel L. García-León

2

0 references

Rosa María Wong-Chew

3

0 references

Angelina Villasís-Keever

4

0 references

Jennifer Cuellar-Rodríguez

5

0 references

Juan L. Mosqueda-Gómez

6

0 references

Teresa Muñoz-Trejo

7

0 references

Kenia Escobedo

8

0 references

José I. Santos

9

0 references

Guillermo M. Ruiz-Palacios

10

0 references

Juan G. Sierra-Madero

Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda.

11

0 references

language of work or name

English

0 references

publication date

November 2009

0 references

published in

Vaccine

0 references

volume

27

0 references

issue

50

0 references

page(s)

7059-7064

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Global measles elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

First 5 years of measles elimination in southern Africa: 1996-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Measles seroprevalence and vaccine response in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Fatal Measles Pneumonia Without Rash in a Child with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Cellular and humoral immune responses to measles in immune adults re‐immunized with measles vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Population immunity to measles virus and the effect of HIV-1 infection after a mass measles vaccination campaign in Lusaka, Zambia: a cross-sectional survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Compromised B cell responses to influenza vaccination in HIV-infected individuals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Loss of memory (CD27) B lymphocytes in HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Response to measles, mumps, and rubella revaccination among HIV-positive and HIV-negative children and adolescents with hemophilia. Hemophilia Growth and Development Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Cellular Immunity in Measles Vaccine Failure: Demonstration of Measles Antigen-Specific Lymphoproliferative Responses despite Limited Serum Antibody Production after Revaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Frequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

The clinical significance of measles: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Vaccine-associated measles pneumonitis in an adult with AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Measles in Mexico, 1941-2001: interruption of endemic transmission and lessons learned.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Prevalence of measles antibodies in asymptomatic human immunodeficiency virus-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Comparison of measles virus-specific antibody titres as measured by enzyme-linked immunosorbent assay and virus neutralisation assay.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063

Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.063